Tenon Medical, Inc. Stock Price, News & Analysis

Tenon Medical (NASDAQ:TNON), a company focused on Sacroiliac Joint (SIJ) disorders treatment, will release its Q2 2025 financial results after market close on Wednesday, August 13, 2025.

The company will host a conference call at 4:30 p.m. Eastern Time on the same day, featuring a Q&A session with covering analysts. The call will be accessible via telephone and webcast, with replay available through August 27, 2025 on Tenon's Investor Relations website.

Tenon Medical (NASDAQ:TNON) has acquired sacroiliac joint-specific assets from SiVantage, including their SImmetry® and SImmetry+™ technologies. The strategic acquisition transforms Tenon into a multi-product, multi-approach sacro-pelvic organization, expanding its portfolio across multiple approaches to sacro-pelvic anatomy.

The transaction brings critical technologies, intellectual property, and key leadership to Tenon, with SiVantage's co-founders joining as Chief Innovations Officer and Chief Commercial Officer. The deal structure includes an upfront cash component and equity issuance, with most consideration tied to future performance milestones. Integration is expected to complete in Q4 2025.

The acquisition immediately strengthens Tenon's product pipeline and is expected to contribute to revenue, supported by extensive clinical data demonstrating safety and performance in sacroiliac joint fusion procedures.

Tenon Medical announced the completion of an initial case series using their Catamaran SI Joint Fusion System to enhance SI Joint stabilization in lumbar fusion procedures. The case series was performed by Dr. Andrew J. Trontis at Progressive Spine & Orthopaedics in New Jersey. This follows the FDA's expanded indication approval for the Catamaran system, allowing its use in sacropelvic fixation during lumbar fusion procedures. Dr. Trontis highlighted that integrating Catamaran into spinal fusion procedures provides robust stabilization without significant complications. CEO Steven Foster emphasized that this expanded indication opens new market opportunities for Tenon by addressing sacropelvic biomechanical challenges in complex spine surgery.

Tenon Medical (NASDAQ: TNON), a healthcare company focused on Sacroiliac Joint (SIJ) disorders, has scheduled its Q1 2025 financial results announcement for May 13, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern Time, featuring a Q&A session with covering analysts.

Investors can access the call through:

• US Dial-in: 1-877-407-0792
• International Dial-in: 1-201-689-8263

Participants are advised to dial in 10 minutes before the call starts. A replay will be available through May 28, 2025, via the company's IR website or by phone (US: 1-844-512-2921, International: 1-412-317-6671) using access code 13752970.

Tenon Medical (NASDAQ:TNON), a company focused on sacroiliac joint disorders treatment, has announced a $2.5 million registered direct offering priced at-the-market under Nasdaq rules. The company will issue 1,271,500 shares of common stock at $2.00 per share to a single healthcare focused institutional investor.

In a concurrent private placement, Tenon will also issue warrants to purchase up to 1,271,500 shares of common stock with an exercise price of $2.00 per share. These warrants will be immediately exercisable and expire after five years.

The offering is expected to close around March 27, 2025. A.G.P./Alliance Global Partners is serving as the sole placement agent. The proceeds will be used for working capital and general corporate purposes.

Tenon Medical (NASDAQ:TNON), a company focused on sacroiliac joint disorders treatment, has announced a registered direct offering and concurrent private placement priced at-the-market under Nasdaq rules. The company will issue 733,500 shares of common stock at $2.00 per share to a single healthcare focused institutional investor.

In the concurrent private placement, Tenon will issue warrants to purchase up to 733,500 additional shares at an exercise price of $2.00 per share, exercisable immediately with a five-year expiration. The offering, expected to close around March 26, 2025, aims to raise approximately $1.5 million in gross proceeds for working capital and general corporate purposes. A.G.P./Alliance Global Partners is serving as the sole placement agent.

Tenon Medical (NASDAQ:TNON) has received FDA clearance for an expanded indication of its Catamaran SI Joint Fusion System. The new clearance allows the device to be used in augmenting thoracolumbar fusion, enabling treatment of the SI joint either as a standalone procedure or to augment spinal fusion.

This regulatory milestone opens up a new market opportunity for the company in complex spine surgery. The Catamaran system's unique design provides physicians with enhanced flexibility in patient treatment. The company's ongoing MAINSAIL clinical trial demonstrates the system's ability to achieve authentic fusion of the SI Joint in a safe, reliable, and efficient manner.

Tenon Medical (NASDAQ:TNON) reported its Q4 and full-year 2024 financial results, showing mixed performance. Full-year revenue reached $3.3 million, marking a 12% increase from 2023, with improved gross profit of $1.7 million and gross margin of 52%.

Q4 2024 revenue remained flat at $0.8 million compared to Q4 2023, while gross profit decreased to $353,000 from $559,000, with margins declining to 46% from 69%. The company's Catamaran SI Joint Fusion System achieved significant milestones, including positive interim results from the MAINSAIL Study and completion of over 1,000 surgical procedures.

Notable developments include the expansion of their patent portfolio to twelve U.S. and international patents, successful initial clinical procedures with the new Catamaran SE platform, and securing an additional $3M in capital in March 2025. The company plans a national commercial launch of Catamaran SE in mid-2025.

Tenon Medical (NASDAQ:TNON), a company focused on sacroiliac joint disorders treatment, has secured $3.0 million in gross proceeds through a warrant inducement transaction with an existing healthcare-focused institutional investor. The agreement involves the immediate exercise of Series A and B Warrants for 2,445,700 total shares at a reduced price of $1.25 per share.

In exchange, the investor will receive new unregistered warrants in a private placement: Series C-1 Warrants for 2,445,700 shares and Series C-2 Warrants for 1,222,850 shares, both with a $1.25 exercise price. The C-1 Warrants will expire in 5 years and C-2 Warrants in 3 years from stockholder approval date. The transaction is expected to close around March 12, 2025.

The company plans to use the net proceeds for working capital and general corporate purposes. A.G.P./Alliance Global Partners served as the exclusive financial advisor for this transaction.